Renaissance Technologies LLC Purchases 311,600 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Renaissance Technologies LLC increased its stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 522.8% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 371,200 shares of the company's stock after buying an additional 311,600 shares during the quarter. Renaissance Technologies LLC owned about 0.47% of Viridian Therapeutics worth $7,116,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. R Squared Ltd purchased a new position in shares of Viridian Therapeutics during the fourth quarter worth $26,000. AlphaQuest LLC increased its holdings in shares of Viridian Therapeutics by 119.0% in the 4th quarter. AlphaQuest LLC now owns 2,795 shares of the company's stock valued at $54,000 after acquiring an additional 1,519 shares during the period. Quantbot Technologies LP purchased a new position in Viridian Therapeutics during the 4th quarter worth $164,000. KLP Kapitalforvaltning AS purchased a new stake in Viridian Therapeutics during the 4th quarter valued at approximately $219,000. Finally, E Fund Management Co. Ltd. acquired a new stake in shares of Viridian Therapeutics during the fourth quarter worth $235,000.

Viridian Therapeutics Stock Up 0.0 %

VRDN stock traded up $0.00 during midday trading on Thursday, hitting $13.51. 95,387 shares of the company's stock were exchanged, compared to its average volume of 1,199,351. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.04. Viridian Therapeutics, Inc. has a 12-month low of $9.90 and a 12-month high of $27.20. The firm has a 50 day moving average price of $14.34 and a 200-day moving average price of $18.40. The stock has a market capitalization of $1.10 billion, a price-to-earnings ratio of -3.13 and a beta of 0.81.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.81) EPS for the quarter, topping analysts' consensus estimates of ($1.05) by $0.24. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. The firm had revenue of $0.07 million during the quarter, compared to the consensus estimate of $0.05 million. On average, analysts anticipate that Viridian Therapeutics, Inc. will post -4.03 EPS for the current year.

Analyst Upgrades and Downgrades

VRDN has been the subject of several analyst reports. Needham & Company LLC reissued a "buy" rating and set a $38.00 price target on shares of Viridian Therapeutics in a report on Tuesday, January 7th. HC Wainwright reiterated a "buy" rating and set a $34.00 target price on shares of Viridian Therapeutics in a research report on Wednesday. Three equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $35.70.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.